Aurinia™ Pharmaceuticals

VOTE to DRIVE VALUE for all shareholders

Vote for AURINIA's Director Nominees on the YELLOW Proxy TODAY

Proxy Voting DEADLINE:
Monday, June 24, 2019 @ 10 a.m. MT

Shareholder Questions and Voting
Laurel Hill Advisory Group
North American Toll Free: 1-877-452-7184
Collect Calls Outside North America: 1-416-304-0211
Email: assistance@laurelhill.com

The Annual General Meeting will be held on Wednesday, June 26, 2019 at 10:00 a.m. MT
At the Westin Calgary, 320 4 Ave SW, Calgary, Alberta T2P 2S6

For further information: www.auriniapharma.com/agm-materials

Aurinia™ Pharmaceuticals

Dear Shareholders,

You are facing an important decision regarding the future value of your investment in Aurinia Pharmaceuticals ("Aurinia" or the "Company").

ILJIN SNT Co., Ltd. ("ILJIN"), a South Korea-based company, is seeking to place three of its nominees on Aurinia's Board of Directors (the "Board"). In addition to failing to provide an alternative strategy for value creation, the dissident has made a series of misleading claims in an attempt to gain representation on the Company's Board far in excess of its ownership.

We strongly believe that adding ILJIN's nominees would impede the significant progress we have made in recent years and disrupt Aurinia's strong momentum as we approach critical milestones.

AURINIA HAS MADE STRONG PROGRESS TO DATE AND IS WELL POSITIONED FOR CONTINUED GROWTH

In the past several years, we have transformed from an early-stage clinical company with one indication to a late-stage clinical development company with multiple indications. We remain keenly focused on unlocking further shareholder value as we prepare for the commercialization of voclosporin.

Voclosporin is a next-generation immunosuppressant compound that has been extensively studied in over 2,600 subjects and aims to address the significant unmet medical needs of patients suffering from lupus nephritis ("LN"), focal segmental glomerulosclerosis ("FSGS"), and dry eye syndrome ("DES").

We continue to take a prudent and disciplined approach to stewarding voclosporin through the Phase 3 AURORA clinical trial for the treatment of LN and are targeting a commercial launch date of early 2021.

Additionally, we are advancing voclosporin ophthalmic solution ("VOS"), a topical formulation, for the treatment of DES, which affects approximately 16 million people in the United States alone[1]. Building upon the recently reported results for VOS, we are actively preparing to launch Phase 2/3 clinical development by the end of 2019.

Critical for a late-stage clinical development company approaching commercialization, we have maintained a strong balance sheet, with approximately $144.3 million USD as of March 31, 2019.

Our progress is creating long-term value for our shareholders. Underscoring just how misleading ILJIN's attacks on our performance are, since Aurinia's rebrand and public market listing in 2013, our share price has performed well above the TSX and Nasdaq biotech indices. Furthermore, Aurinia has delivered strong annualized total shareholder returns relative to relevant indices and the broader market.

[1] https://www.ncbi.nlm.nih.gov/pubmed/28705660

Average Annualized Total Shareholder Returns	One-Year	Three-Year	Five-Year
Aurinia Pharmaceuticals Inc. (AUPH:US)	20.1%	40.9%	21.0%
S&P/TSX Capped Health Care Index (^TTHC)	31.4%	8.6%	5.7%
S&P/TSX Composite Index (^TSX)	0.7%	5.2%	2.0%
NASDAQ Composite Index (^COMPX:US)	2.9%	16.3%	12.8%

Today, we are transitioning through several important milestones, and we expect our share price to ultimately reflect the value we are creating for shareholders. Aurinia has strong forward momentum and the right strategy in place to enhance value for all shareholders.

AURINIA IS COMMITTED TO STRONG GOVERNANCE

We are committed to implementing robust governance practices that best support long-term value creation for all our shareholders. To this end, we have consistently pursued thoughtful and responsible compensation practices that align our management's interests with those of our shareholders. Our Compensation Committee consists entirely of independent Directors – including Dr. Hyuek Joon Lee, ILJIN's representative on our Board – and undertakes a deliberate process involving well-established and experienced outside consultants to develop compensation packages that incentivize long-term value creation.

Contrary to ILJIN's misleading claims, the salaries for our named executive officers ("NEOs") are generally in the bottom 25th percentile of our 2019 compensation peer group. Furthermore, total compensation packages (including bonuses and equity compensation) for our NEOs are approximately at the 50th percentile of our peer group.

Our continuous efforts to refresh our Board further reflect our commitment to strong governance. Five of our eight Directors have joined the Board since 2016, bringing fresh perspectives and extensive experience in clinical development, regulatory submissions, and commercialization, particularly in the United States, where we will be making a regulatory submission. In addition, six of our eight director nominees are independent.

Furthermore, we remain committed to continually evaluating governance and Board composition as our Company evolves and as we continue to engage our shareholders. We recently separated the CEO and Chairman roles and are planning to introduce minimum equity ownership requirements for Directors.

Additionally, as ILJIN is aware, the Board has already committed to increasing gender diversity as part of its Director recruiting efforts.

ILJIN's continued focus on Dr. Glickman, who no longer serves as CEO or a Director of Aurinia, is puzzling. As is common practice, Aurinia asked Dr. Glickman to serve as a consultant to oversee the transition of his role and to facilitate a seamless transition for Peter Greenleaf when he assumed the role as Aurinia's new

CEO this past April. The fact that Dr. Glickman holds this transitional role in no way impedes the Board's ability to act independently.

ILJIN HAS PRESENTED NO PLAN OR ACTIONABLE IDEAS

Despite our repeated attempts at constructive dialogue with ILJIN, it has disclosed no alternative strategy for value creation. Beyond advocating governance measures (many of which were already underway at the Company – efforts that ILJIN was already well aware of given its Board representation) ILJIN has offered no specific, additive or constructive insights or ideas.

Instead of engaging us in good faith, ILJIN has decided to wage a costly and unnecessary proxy contest. That ILJIN would distract the Company at such a critical time, as we focus on commercialization, is particularly troubling.

ILJIN's NOMINEES LACK THE EXPERTISE AND QUALIFICATIONS THE COMPANY NEEDS AT THIS CRITICAL TIME

While ILJIN concurs with our view that the Company's shift to commercialization should be our focus right now, the dissident's nominees have little-to-no experience in this area. This contrasts sharply with our nominees, who have proven track records in the successful commercialization of drugs.

Importantly, our Board includes biotechnology leaders who have successfully led and transitioned their companies from therapy concept to revenue generation. These are exactly the types of directors we need to advance and successfully commercialize while at the same time ensuring we remain well-capitalized and focused on delivering shareholder value.

Peter Greenleaf, our new CEO, is an experienced biotech CEO and Director who has taken therapies through to commercialization, all the while creating significant shareholder value. He brings the depth and breadth of experience we need to take Aurinia to its next stage of development by continuing to grow and advance our pipeline.

ILJIN nonetheless wishes to replace our highly qualified Director nominees with its own hand-picked nominees. ILJIN has failed to articulate how any of its nominees would benefit the Company at this critical juncture and how they would provide the commercialization expertise it agrees is needed on the Board.

Furthermore, ILJIN's public communications around the proxy contest demonstrate a lack of knowledge regarding how to run successful trials and commercialize therapies. They question rising expenses, but ignore the larger size of current trials, the need for additional patient recruitment in the U.S. for FDA approval, and the investment required in planning for commercialization for swift launch following potential approval. It's troubling that ILJIN's nominees did not inform ILJIN of these commercial realities.

ILJIN HAS PRESENTED CONTINUOUSLY CHANGING DEMANDS WHILE REJECTING AURINIA'S EFFORTS TO NEGOTIATE IN GOOD FAITH; ILJIN'S MOTIVES ARE UNCLEAR

The Board has communicated consistently with and listened carefully to ILJIN's questions and feedback since ILJIN's initial investment in the Company. We regret that despite continual negotiations to work toward a mutual agreement, they have resisted and instead turned this into a public proxy battle. ILJIN's demands included:

- **Ever-changing Director Nominees**: For example, since first reaching out to Aurinia on March 12, 2019 to propose potential Director nominees, ILJIN has amended its proposed slate of Director nominees on no less than five separate occasions, with the latest change occurring on June 3, 2019 in ILJIN's proxy circular of the same date.
- **Unwillingness to Settle**: Aurinia has repeatedly attempted to negotiate with ILJIN in good faith. In addition to numerous conference calls, in early May, mere days after his appointment as our CEO, Peter Greenleaf spent two days with ILJIN in South-Korea, with the specific intention of reaching an agreement on the Board slate.

When looking at ILJIN's pattern of ever-changing demands, volatile negotiation tactics and unclear motives, we can only assume that the activist is seeking to gain control of the Company without a clear plan and without paying a premium to shareholders.

Despite holding less than 15% of Aurinia's outstanding shares, and already having a representative on the Company's Board in Dr. Hyuek Joon Lee, the dissident is seeking three new Board seats. This level of representation is hardly commensurate with ILJIN's holdings.

PROTECT THE VALUE OF YOUR INVESTMENT – VOTE THE YELLOW PROXY TODAY.

Aurinia's success in rapid advancement of key therapies, pipeline growth, and fundraising demonstrates the quality and effectiveness of our Board. We have the right Board and management team in place to lead Aurinia to its next stage of growth as we approach commercialization.

Your vote is extremely important, regardless of how many shares you own. Protect the value of your investment by voting the YELLOW proxy today.

On behalf of the Special Committee of the Board of Directors of Aurinia Pharmaceuticals Inc.,

(signed) "Peter Greenleaf"
Peter Greenleaf
Chief Executive Officer

(signed) "George Milne"
George Milne, Ph.D.
Chairman of the Board

Vote the YELLOW proxy well in advance of the Proxy Voting Cut-Off of 10:00 A.M. (Mountain time) on June 24, 2019.

Voting Method	Registered Shareholders If your shares are held in your name and represented by a physical certificate or in a direct registration system.	Non-Registered Shareholders If your shares are held with a broker, bank or other intermediary.
Internet	Not available	www.proxyvote.com
Facsimile	North American toll free: 1-866-249-7775 Outside North America: 416-263-9524	Complete, date, and sign the **YELLOW** voting instruction form and fax it to the number listed therein.
Telephone	Not available	Call the toll-free number listed on your **YELLOW** voting instruction form and vote using the control number provided therein.
Mail	Complete, date and sign the **YELLOW** proxy and return in the enclosed postage paid envelope to: **Computershare Investor Services Inc.** 100 University Avenue, 8th Floor, Toronto, Ontario M5J 2Y1.	Complete, date and sign the **YELLOW** voting instruction form and return it in the enclosed postage paid envelope.

QUESTIONS OR REQUESTS FOR ASSISTANCE WITH VOTING MAY BE DIRECTED TO AURINIA'S PROXY SOLICITATION AGENT:

LH LAUREL HILL ADVISORY GROUP

NORTH AMERICAN TOLL FREE
1-877-452-7184

COLLECT CALLS OUTSIDE NORTH AMERICA
1-416-304-0211

EMAIL
ASSISTANCE@LAURELHILL.COM